You are here

Article Text

Article menu
Download PDFPDF
Featured correspondence
Effects of glycoprotein IIb/IIIa blockers
  1. Arun Kalyanasundaram1,
  2. Peter Berger1,
  3. Adnan Kastrati2
  1. 1
    Geisinger Medical Centre, Danville, PA, USA
  2. 2
    German Heart Center, Munich, Germany
  1. Dr A Kalyanasundaram, 21–60, Department of Cardiology, 100 North Academy Drive, Danville, PA 17822, USA; Aksundaram1{at}geisinger.edu

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor: The meta-analysis by Hernandez et al1 showed that the reduction of death or non-fatal myocardial infarction with IIb/IIIa inhibitors in patients with an acute coronary syndrome (ACS) was independent of patient age. The trials included were performed before widespread administration of clopidogrel in ACS.

    Clopidogrel has been shown to be beneficial …

    View Full Text

    Footnotes

    • Competing interests: None declared.